Research programme: peptide-based immunotherapeutics - Bionor PharmaAlternative Names: Vacc CMV; Vacc Flu; Vacc HCV; Vacc HPV; Vacc-CMV (cytomegalovirus vaccine) - Bionor Pharma; Vacc-Flu (universal influenza vaccine) - Bionor Pharma; Vacc-HCV (hepatitis C vaccine) - Bionor Pharma; Vacc-HIV; Vacc-HPV (human papillomavirus vaccine) - Bionor Pharma
Latest Information Update: 05 Jul 2016
At a glance
- Originator Bionor Immuno
- Developer Bionor Pharma
- Class Peptides; Viral vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes - Cervical cancer; Cytomegalovirus infections; Hepatitis C; Human papillomavirus infections; Influenza virus infections
Highest Development Phases
- Preclinical Cervical cancer; Hepatitis C; HIV infections; Human papillomavirus infections; Influenza virus infections